Clinical characteristics and prognosis of primary testicular diffuse large B-cell lymphoma
10.12007/j.issn.0258-4646.2023.11.004
- VernacularTitle:原发性睾丸弥漫大B细胞淋巴瘤的临床特征与预后分析
- Author:
Shike LI
1
;
Wenyu SHI
;
Zhuo ZHANG
;
Feng ZHANG
;
Xiuhua SUN
Author Information
1. 大连医科大学研究生院,辽宁 大连 116044;南通大学附属医院肿瘤科,江苏 南通 226001
- Keywords:
primary testicular lymphoma;
diffuse large B-cell lymphoma;
clinical characteristics;
prognosis
- From:
Journal of China Medical University
2023;52(12):1074-1081
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical characteristics and prognosis of primary testicular diffuse large B-cell lymphoma(PT-DLBCL).Methods The clinical data,treatment regimen and prognosis of PT-DLBCL patients were analyzed retrospectively,from the records of the Affiliated Hospital of Nantong University and the Second Affiliated Hospital of Dalian Medical University from Jan.1,2000 to Dec.31,2022.Results The median age of the 47 PT-DLBCL patients was 64 years old.The median overall survival(OS)was 41.6 months,with 1-year,3-year,and 5-year PT-DLBCL OS of 93%,77%,and 59%,respectively.Kaplan-Meier univariate analysis demonstrated that a diagnosed age≥70 years,Eastern cooperative oncology group(ECOG)score≥3,international prognostic index(IPI)score≥4,no combination of anthracycline and rituximab,a single treatment regimen,ineffective initial treatment and relapse,were asso-ciated with an adverse prognosis in PT-DLBCL(all P<0.05).Multivariate Cox regression analysis showed that an ECOG score≥3,no application of Rituximab,and an ineffective initial treatment response were independent risk factors for the poor prognosis of PT-DLBCL(all P<0.05).Conclusion PT-DLBCL is rare and associated with a poor prognosis.Early diagnosis and therapy with a combination of anthracyclines and rituximab may improve outcomes.
